$599

Amgen, Novartis, and Lannett Q4 ’22 Earnings Updates

A series of cardiometabolic-related news items have been observed. Amgen (press release; slides), Novartis (press release; slides), and Lannett (press release) hosted their respective Q4 2022 earnings calls. Below, FENIX provides highlights and insights from the earnings calls.

This content is for Read Less members only.
Register
Already a member? Log in here